OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
U.S. Condemns South Africa’s Expulsion of Israeli Diplomat Amid Rising Diplomatic Tensions 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
The US Food and Drug Administration (FDA) is planning to regulate the use of the cannabis compound CBD in food and supplements after weighing the evidence on the compound's safety.
The FDA will decide whether regulating legal cannabis will require new agency rules or new legislation from Congress.
Cannabis products, excluding Epidiolex, are illegal at the federal level in the US, although some states allow their use.
According to Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, the FDA will ascertain if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility.
.
